RET and neoplasm: Interestingly, the genetic characterization of the 14 FPTCs, for whom the tumor tissue was available, revealed a BRAFV600E mutation in 4/14 (28.6%) cases, a RET fusion in 2/14 (14.3%) (1 with ret/PTC1 and 1 ret/PTC3), a TERT c.-124C>T mutation in 2/14 (14.3%), while 1/14 (7.1%) tumor harbored both NRASQ61K and TERT c.-146C>T mutations, and 1/14 both BRAFV600E and TERT c.-124C>T genetic variations.